Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study
- PMID: 22147713
- PMCID: PMC3233986
- DOI: 10.7326/0003-4819-155-11-201112060-00006
Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study
Abstract
Background: Prior studies have found inverse associations between high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I levels and cardiovascular disease (CVD). Whether this observation is consistent across low-density lipoprotein cholesterol (LDL-C) levels or total atherogenic particle burden (apolipoprotein B100) is less well-studied, particularly in women.
Objective: To determine the association between HDL-C or apolipoprotein A-I level and CVD across a range of LDL-C and apolipoprotein B100 values.
Design: Prospective cohort study.
Setting: The Women's Health Study, a cohort of U.S. female health professionals.
Participants: 26,861 initially healthy women, aged 45 years or older at study entry (1992-1995), who were followed for a mean of approximately 11 years.
Measurements: Baseline lipids were measured directly, and apolipoproteins were measured with immunoassays. Outcomes were incident total CVD (n = 929), coronary events (n = 602), and stroke (n = 319).
Results: In multivariable analyses, HDL-C and apolipoprotein A-I levels were inversely associated with CVD and coronary events but not stroke. Adjusted coronary hazard ratios for decreasing quintiles of HDL-C were 1.00 (reference), 1.23 (95% CI, 0.85 to 1.78), 1.42 (CI, 0.98 to 2.06), 1.90 (CI, 1.33 to 2.71), and 2.19 (CI, 1.51 to 3.19) (P for linear trend < 0.001); corresponding hazard ratios for apolipoprotein A-I were 1.00 (reference), 0.98 (CI, 0.71 to 1.35), 1.02 (CI, 0.72 to 1.44), 1.37 (CI, 0.98 to 1.90), and 1.58 (CI, 1.14 to 2.20) (P for linear trend = 0.005). Consistent inverse associations were found for HDL-C with coronary events across a range of LDL-C values, including among women with low LDL-C levels. No associations were noted for HDL-C or apolipoprotein A-I among women with low apolipoprotein B100 values (<0.90 g/L).
Limitation: Participants were at low risk for CVD, the number of events in the lowest apolipoprotein B100 stratum was small, only a single baseline measurement was obtained, and residual confounding may have occurred.
Conclusion: Consistent inverse associations were found for HDL-C with incident coronary events among women with a range of LDL-C values. Among women with low total atherogenic particle burden (apolipoprotein B100 level <0.90 g/L), few events occurred and no associations were seen.
Primary funding source: Merck & Co. and the National Heart, Lung, and Blood Institute and National Cancer Institute, National Institutes of Health.
Figures



Summary for patients in
-
Summaries for patients. Does low-density lipoprotein cholesterol influence the relationship between high-density lipoprotein cholesterol and cardiovascular risk in women?Ann Intern Med. 2011 Dec 6;155(11):I56. doi: 10.7326/0003-4819-155-11-201112060-00003. Ann Intern Med. 2011. PMID: 22147728 No abstract available.
Similar articles
-
Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.J Am Heart Assoc. 2016 Oct 13;5(10):e003665. doi: 10.1161/JAHA.116.003665. J Am Heart Assoc. 2016. PMID: 27737874 Free PMC article.
-
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.JAMA. 2005 Jul 20;294(3):326-33. doi: 10.1001/jama.294.3.326. JAMA. 2005. PMID: 16030277
-
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.PLoS Med. 2020 Mar 23;17(3):e1003062. doi: 10.1371/journal.pmed.1003062. eCollection 2020 Mar. PLoS Med. 2020. PMID: 32203549 Free PMC article.
-
Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.Pathology. 2019 Feb;51(2):148-154. doi: 10.1016/j.pathol.2018.11.006. Epub 2018 Dec 27. Pathology. 2019. PMID: 30595507 Review.
-
Pitavastatin: novel effects on lipid parameters.Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
Cited by
-
Type 2 diabetes and cardiovascular disease in women.Diabetologia. 2013 Jan;56(1):1-9. doi: 10.1007/s00125-012-2694-y. Epub 2012 Sep 4. Diabetologia. 2013. PMID: 22945305 Review.
-
Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE).J Stroke. 2022 May;24(2):224-235. doi: 10.5853/jos.2021.02152. Epub 2022 May 31. J Stroke. 2022. PMID: 35677977 Free PMC article.
-
Acute and Sub-Acute Toxicity Studies of Plumeria alba Linn. (Apocynaceae) Hydroalcoholic Extract in Rat.Int J Biomed Sci. 2013 Dec;9(4):255-9. Int J Biomed Sci. 2013. PMID: 24711763 Free PMC article.
-
Sex-Related Differences of the Effect of Lipoproteins and Apolipoproteins on 10-Year Cardiovascular Disease Risk; Insights from the ATTICA Study (2002-2012).Molecules. 2020 Mar 26;25(7):1506. doi: 10.3390/molecules25071506. Molecules. 2020. PMID: 32225033 Free PMC article.
-
Effects of Tributyrin Supplementation on Liver Fat Deposition, Lipid Levels and Lipid Metabolism-Related Gene Expression in Broiler Chickens.Genes (Basel). 2022 Nov 26;13(12):2219. doi: 10.3390/genes13122219. Genes (Basel). 2022. PMID: 36553486 Free PMC article.
References
-
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421. - PubMed
-
- Walldius G, Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med. 2006;259:493–519. - PubMed
-
- Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–714. - PubMed
-
- Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol. 1988;4 (Suppl A):5A–10A. - PubMed
-
- Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35:779–92. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical